<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00296582</url>
  </required_header>
  <id_info>
    <org_study_id>65-06</org_study_id>
    <nct_id>NCT00296582</nct_id>
  </id_info>
  <brief_title>Gastric Motor Function Measurement in Dyspepsia and Normal Subjects</brief_title>
  <official_title>Simultaneous Gastric Motor Function Measurement in Dyspepsia And Normal Subjects Ingesting a Solid-Liquid Meal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to measure the functions of the stomach after eating a meal and to&#xD;
      develop a new method that will simultaneously measure both gastric emptying and the&#xD;
      relaxation of the stomach after a meal using nuclear medicine testing. This would make the&#xD;
      testing more convenient for patients and will also offer better understanding of these two&#xD;
      gastric functions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fasting and postprandial gastric volumes (Gastric accommodation)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>T1/2 of gastric emptying of solid</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum tolerated volume</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual postprandial symptom scores</measure>
  </secondary_outcome>
  <enrollment type="Actual">30</enrollment>
  <condition>Dyspepsia</condition>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Gastric Motor Function Measurement</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        Dyspeptic Subjects:&#xD;
&#xD;
          -  Recurrent episodes of upper abdominal pain or discomfort including early satiety,&#xD;
             fullness, bloating, or nausea for at least 3 months in the prior year.&#xD;
&#xD;
          -  A baseline impaired satiety test (maximum tolerated volume 25% of normal or 1000cc).&#xD;
&#xD;
          -  No evidence on esophagogastroduodenoscopy of erosions, peptic ulcer, pyloric&#xD;
             obstruction, esophagitis or malignancy in the prior 3 years.&#xD;
&#xD;
        All Subjects:&#xD;
&#xD;
          -  No history suggestive of small bowel obstruction.&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  No structural or metabolic diseases/conditions that affect the gastrointestinal&#xD;
             system.&#xD;
&#xD;
          -  Unable to stop medications 48 hours prior to the study that:&#xD;
&#xD;
               -  Alter GI transit including laxatives, magnesium or aluminum-containing antacids,&#xD;
                  prokinetics, erythromycin, narcotics, anticholinergics, tricyclic&#xD;
                  antidepressants, SSRI and newer antidepressants.&#xD;
&#xD;
               -  Analgesic drugs including opiates, NSAID, COX 2 inhibitors&#xD;
&#xD;
               -  Systemic antifungal drugs&#xD;
&#xD;
               -  Carbamazepine, glucocorticoids, phenobarbital, phenytoin, rifampin, but also&#xD;
                  grapefruit juice.&#xD;
&#xD;
               -  Benzodiazepines NOTE: Low stable doses of thyroid replacement, estrogen&#xD;
                  replacement, low dose aspirin for cardioprotection and birth control pills or&#xD;
                  depot injections are permissible.&#xD;
&#xD;
          -  Female subjects who are pregnant or breast feeding.&#xD;
&#xD;
          -  Significant cardiovascular, respiratory, renal, hepatic, gastrointestinal,&#xD;
             hematological, neurological, psychiatric, or other disease that interfere with the&#xD;
             objectives of the study.&#xD;
&#xD;
          -  Subjects who have participated in another clinical study within the past 30 days.&#xD;
&#xD;
          -  Previous gastric or intestinal surgery (except appendectomy , cholecystectomy or&#xD;
             hysterectomy).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>H. Jae Kim, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <study_first_submitted>February 24, 2006</study_first_submitted>
  <study_first_submitted_qc>February 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2006</study_first_posted>
  <last_update_submitted>May 20, 2011</last_update_submitted>
  <last_update_submitted_qc>May 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 23, 2011</last_update_posted>
  <responsible_party>
    <name_title>Hack Jae Kim, M.D.</name_title>
    <organization>Mayo Clinic</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspepsia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

